암치료용 유전체학 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 기술별, 지역별, 부문 예측(2024-2030년)

Genomics In Cancer Care Market Growth & Trends:

The global genomics in cancer care market size is expected to reach USD 50.97 billion by 2030, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 16.0% from 2024 to 2030. Increasing prevalence of cancer coupled with adoption of next generation sequencing for the diagnosis & treatment is expected to fuel the market with future growth opportunities. Increasing incidences of cancer triggers the demand for cost effective and accurate diagnostics in coming years.

In addition, increasing demand for personalized medicines in molecular characterization of cancer to identify therapeutic targets is the factor attributing towards the market growth. Similarly, factors such as cost reduction in genome sequencing, growing healthcare expenditure levels and development of effective diagnostics & therapeutic procedures for cancer are responsible for the potential growth of genomics in cancer care.

Genomics In Cancer Care Market Report Highlights:

• Instrument segment dominated the overall market in terms of revenue share as of 2023 and accounted for 54.8% of market owing to high cost associated with it. Whereas, consumables are most widely used product segment in genome testing as they are indispensible component and frequently required to perform the test.
• Demand for services such as next generation sequencing, PCR and other such as cancer risk management & genetic testing are expected to grow over the forecast period due to increasing outsourcing activities to perform genome analysis. High cost of performing genetic tests and growing awareness pertaining to associated benefits with the use of these technologies are high impact rendering drivers for this segment.
• Drug discovery and development segment is expected to show lucrative CAGR of 18.5% during the forecast period owing to increasing demand for effective treatment for cancer and growing investment in biomedicines by manufacturers for the development of novel products.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Genomic in Cancer Care Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Genomic in Cancer Care Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Genomics in Cancer Care Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Genomics in Cancer Care Market: Product Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Instruments
  • 4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Consumables
  • 4.4.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Genomics in Cancer Care Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Genomics in Cancer Care Market: Application Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. Diagnostics
  • 5.3.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Personalized Medicine
  • 5.4.1. Personalized Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Drug Discovery & Development
  • 5.5.1. Drug Discovery & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Research
  • 5.6.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Genomics in Cancer Care Market: Technology Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Genomics in Cancer Care Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
• 6.3. Genome Sequencing
  • 6.3.1. Genome Sequencing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. PCR
  • 6.4.1. PCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Microarrays
  • 6.5.1. Microarrays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Nucleic Acid Extraction & Purification
  • 6.6.1. Nucleic Acid Extraction & Purification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Other
  • 6.7.1. Other Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Genomics in Cancer Care Market: Regional Estimates & Trend Analysis

• 7.1. Genomics in Cancer Care Market Share, By Region, 2023 & 2030 (USD Million)
• 7.2. North America
  • 7.2.1. North America Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.K.
    • 7.3.2.1. U.K. Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. China
    • 7.4.2.1. China Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Japan Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Australia Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Saudi Arabia Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. UAE
    • 7.6.3.1. UAE Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. South Africa
    • 7.6.4.1. South Africa Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Agilent Technologies, Inc.,
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. F. Hoffmann-La Roche Ltd
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. Beckman Coulter, Inc.,
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. Illumina Inc.
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Abbott
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Cancer Genetics Inc.
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. Bio-Rad Laboratories
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. PacBio
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. GE Healthcare
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Quest Diagnostics Incorporated
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives
  • 8.4.11. PerkinElmer
    • 8.4.11.1. Participant's Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Recent Developments/ Strategic Initiatives
  • 8.4.12. Luminex
    • 8.4.12.1. Participant's Overview
    • 8.4.12.2. Financial Performance
    • 8.4.12.3. Product Benchmarking
    • 8.4.12.4. Recent Developments/ Strategic Initiatives